Within the varicose veins treatment devices market, sclerotherapy held a 67.9% share in 2025, reflecting its established role in routine vein treatment across a broad patient base. its position is underpinned by consistent clinical use in treating smaller varicose and spider veins, along with its fit in office-based care settings where procedural simplicity and repeatable treatment workflows support continued demand. The segment’s strong share also reflects how deeply embedded sclerotherapy is in standard treatment pathways for patients who do not require more device-intensive intervention.

Endovenous ablation is emerging as the fastest-growing segment in the varicose veins treatment devices market because treatment preferences are shifting toward minimally invasive options that can address symptomatic venous insufficiency with more targeted procedural control. Growth is being aided by increasing adoption in cases where clinicians seek an alternative to conventional approaches with streamlined recovery and stronger suitability for larger incompetent veins. Relative to other treatment types, endovenous ablation is gaining momentum as providers expand procedural capabilities and patients increasingly favor less disruptive interventions.

End Use Segment Analysis: Hospitals (Largest Segment) vs Ambulatory Care Unit (Fastest-Growing Segment)

Hospitals accounted for the largest share of the varicose veins treatment devices market in 2025, aided by their ability to manage a wide range of vein procedures within integrated care environments. Their leading share is reinforced by access to multidisciplinary specialists, procedural infrastructure, and the capacity to treat patients requiring diagnostic evaluation and intervention in the same setting. This makes hospitals a dependable end-use channel for varicose veins treatment devices, particularly where treatment decisions are tied to broader vascular care pathways.

Ambulatory care unit is the fastest-growing end-use segment in the varicose veins treatment devices market as vein procedures increasingly move toward outpatient settings built around efficiency and shorter patient turnaround times. Growth is being encouraged by the practical fit between minimally invasive treatment methods and care models that reduce facility burden while maintaining procedural accessibility. Compared with traditional inpatient-oriented settings, ambulatory care units are experiencing stronger uptake because they align more closely with evolving provider workflows and patient expectations for convenient treatment.